Barcelona will host from April 27 to 30 the 34^th edition of the ESCMID Global congress where HIPRA will present its main research and development projects at its stand (C-16). New clinical data of its Omicron XBB-adjuvanted COVID-19 vaccine compared to an XBB-adjuvanted mRNA vaccine against SARS-CoV-21 variants XBB and JN.1¹ will also be shown. 

The booth will also showcase innovations from GoodGut, the HIPRA group company dedicated to the development of solutions for the diagnosis of digestive diseases based on the intestinal microbiota.

Symposium on COVID-19 booster vaccination

In the framework of the congress, HIPRA has organized a symposium under the title "COVID-19 booster vaccination: key drivers for sustained protection". It will take place on April 27 at 1:30 pm in Hall O, and will highlight the importance of scientific data in terms of strategic vaccination:

^{1.  Lopez MJ, Narejos S, Castro A, et al. Immunogenicity and safety of an Omicron XBB.1.16 adapted vaccine for COVID-19: Interim results from a randomized, controlled, non-inferiority clinical trial. MedRxiv 2024. DOI: 10.1101/2024.04.19.24306064}